Future Science Group
Browse
Supplementary Figures 1-6.pdf (139.26 kB)

Propargylamine: an important moiety in drug discovery - Supplementary Figures

Download (139.26 kB)
figure
posted on 2023-02-21, 09:08 authored by Aitor Carneiro, Eugenio Uriarte, Fernanda Borges, Maria Jo˜ao Matos

Supplementary Figure 1. Chemical structures of the FDA-approved drugs rasagiline and

selegiline/deprenyl.

Supplementary Figure 2. Metabolic pathways that propargylamine derivatives may undergo within the

body according to different publications in the literature [8,9].

Supplementary Figure 3. Proposed mechanism of activation of propargylamine-based MAO inhibitors by

Albreht et al. [26].

Supplementary Figure 4. Propargylamine-based radioligands for PET imaging of MAO-A and MAO-B

highlighted in the work by Narayanaswami et al. [33].

Supplementary Figure 5. Chemical structure of ladostigil, a propargylamine-based clinical candidate that

acts as a MAO and AChE–BuChE dual inhibitor.

Supplementary Figure 6. General scheme of the copper-catalyzed azide–alkyne cycloaddition (CuAAC),

one of the most used bioorthogonal click chemistry reactions [69].

Funding

Fundação para a Ciência e a Tecnologia, (Grant / Award Number: '2021.05149.BD','CEECIND/02423/2018','EXPL/BIA-BQM/0492/2021','LA/P/0056/2020','PTDC/ASP-PES/28397/2017','PTDC/MED-QUI/29164/2017','UIDB/00081/2020') Ministerio de Ciencia e Innovación, (Grant / Award Number: 'PID2020-116076RJ-I00/AEI/10.13039/501100011033')

History

Usage metrics

    Future Medicinal Chemistry

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC